Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Combination for Refractory/Relapsed Pediatric Brain Tumors
NCT01535183Phase 2Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Jan 2012
- Primary completion
- Sep 2016
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in brain tumor, sponsored by Seoul National University Hospital. Status: unknown.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
brain tumor
Beyond the preview
Go deeper on NCT01535183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01535183.